Skip to content
Hair Pipeline
enfr
← Back to the pipeline

Minoxidil (low-dose oral)

Minoxidil (low-dose oral) is marketed for another indication and used off-label for androgenetic alopecia.

The same molecule, swallowed at a fraction of the blood-pressure dose: widely prescribed off-label, and not approved for hair anywhere this register can find.

Marketed, off-labelOralPotassium channel opener

Monthly digest of verified phase changes. A confirmation link goes out first; unsubscribe is one click on every mail.

Developed by
Not recorded
Current phase
Marketed, off-label

Approved for something else and prescribed off-label for hair loss.

Mechanism
Potassium channel opener

Opens potassium channels in the follicle - minoxidil's mechanism, thought to improve blood flow and prolong the growth phase.

Indications
Androgenetic alopecia, Female pattern hair loss
Also known as
oral minoxidil, low-dose oral minoxidil, LDOM, minoxidil oral
Last public activity
September 2026
Copy last reviewed
September 2026
Record confidence
High

A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.

How it is meant to work

Oral minoxidil is approved as an antihypertensive, in the US since 1979, not for hair loss; prescribing it at low doses for alopecia is off-label, and the practice grew out of dermatology case series rather than a registration programme. Reviews describe typical doses of 0.5 to 5 mg a day, well below the 10 to 40 mg of the blood-pressure label, with hypertrichosis, unwanted hair elsewhere on the body, as the most common adverse effect; the antihypertensive label's warnings on fluid retention and pericardial effusion still apply to the molecule.

Why it matters

It is in the register as an honest marker of where the field actually is. One of the most widely used systemic options for pattern hair loss is a repurposed 1970s antihypertensive, prescribed off-label on the strength of case series rather than a registration programme. That is now changing from two directions: Industrial Farmacéutica Cantabria has been running a 520-participant Phase 3 of oral minoxidil 1 mg in female androgenetic alopecia in Germany, Italy, Portugal and Spain since October 2024, against both placebo and topical minoxidil, with primary completion due in October 2026, and Veradermics is taking an extended-release tablet through registrational trials in the US, as its own entry records. A positive readout would be the first step towards a label, not the label itself.

Where it is approved

Marketing authorisation is granted country by country, for a specific indication. A drug approved for hair loss in one market may be approved only for something else — or not at all — in another.

  • United StatesFDAOff-label· prescription only

    Oral minoxidil is authorised as an antihypertensive. No authority has approved it for hair loss, so every prescription for alopecia is off-label.

    Peer-reviewed ↗

Development history

  1. Phase 2Phase 3

    First Phase 3 trial on record: NCT05888922 — Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

    ClinicalTrials.gov ↗
  2. Phase 2

    First Phase 2 trial on record: NCT05778825 — A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT07018349UnknownNot yet recruiting

    Low Dose Oral Minoxdil in Androgenic Alopecia

    Jinnah Postgraduate Medical Centre · n=76 · June 2025

  • NCT05778825Phase 2Active, not recruiting

    A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

    Memorial Sloan Kettering Cancer Center · n=10 · March 2023

  • NCT03831334Phase 0Active, not recruiting

    Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

    Northwestern University · n=14 · April 2019

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources

Related programmes

Other programmes in the register with the same mechanism: Potassium channel opener.

Cite this page

Hair Pipeline, "Minoxidil (low-dose oral) — development record", hairpipeline.com/pipeline/minoxidil-oral-low-dose